CREB3L1 and bladder transitional cell carcinoma: In addition, the PFS analysis suggested that CREB3L1 plays a protective role in patients with ACC (HR, 0.770; 95% CI, 0.604-0.982; p = 0.035), PRAD (HR, 0.640; 95% CI, 0.504-0.812; p < 0.001) and UCEC (HR, 0.830; 95% CI, 0.754-0.915; p < 0.001) and a risk role in patients with BLCA (HR, 1.124; 95% CI, 1.005-1.256; p = 0.041), KIRC (HR, 1.341; 95% CI, 1.167-1.541; p < 0.001) and KIRP (HR, 1.344; 95% CI, 1.132-1.594; p < 0.001) (Figure 3D).